CELZ (Creative Medical Technology Holdings) Net Income: $-6.04 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELZ Creative Medical Technology Holdings Inc CELZ
28 GF Score
Price $1.13
GF Value $0.49
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Net Income?

Creative Medical Technology Holdings CELZ +2.28% 28 Net Income is $-6.04 Mil as of Jun. 2026. GuruFocus rates CELZ with a GF Score™ of 28/100 and a GF Value™ of $0.49 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Creative Medical Technology Holdings's Net Income for the three months ended in Jun. 2026 was $-1.51 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.04 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Creative Medical Technology Holdings's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.41.


Creative Medical Technology Holdings  (NAS:CELZ) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Creative Medical Technology Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Creative Medical Technology Holdings Net Income Related Terms


Creative Medical Technology Holdings Net Income Historical Data

* Premium members only.

The historical data trend for Creative Medical Technology Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Medical Technology Holdings Net Income Chart

Creative Medical Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.21 -10.14 -5.29 -5.49 -6.00

Creative Medical Technology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.23 -1.24 -1.89 -1.41 -1.51
CELZ
28GF Score
Creative Medical Technology Holdings Inc CELZ
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creative Medical Technology Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Creative Medical Technology Holdings's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-5.995+0+0+0
=-6.00

Creative Medical Technology Holdings's Net Income for the quarter that ended in Jun. 2026 is calculated as

Net Income(Q: Jun. 2026 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.511+0+0+-0.0010000000000001
=-1.51

Net Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of $-6.04 Mil mean?
Creative Medical Technology Holdings (CELZ) has a Net Income of $-6.04 Mil as of Jun. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Creative Medical Technology Holdings and its competitors.
Is Creative Medical Technology Holdings' Net Income too high?
Creative Medical Technology Holdings' current Net Income is $-6.04 Mil. Overall, Creative Medical Technology Holdings has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Net Income compare to MLEC and DRMA?
Creative Medical Technology Holdings' Net Income of $-6.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Creative Medical Technology Holdings and its competitors. Creative Medical Technology Holdings's current Net Income is $-6.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.49, compared to a current price of $1.13 — trading 130.6% above its estimated fair value. The current Net Income is $-6.04 Mil. Creative Medical Technology Holdings' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Net Income is $-6.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $1.13 is trading 130.6% above its estimated GF Value™ of $0.49. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Net Income: $-6.04 Mil
  • GF Value™: $0.49 vs. price of $1.13 (130.6% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
28GF Score

Get the complete analysis for CELZ

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price
$0.49
GF Value